adc therapeutics is a biotechnology company located in lausanne, vaud, switzerland.
Company profile
Ticker
ADCT
Exchange
Website
CEO
Christopher John Martin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
ADCT stock data
Latest filings (excl ownership)
8-K
Corporate Presentation 2Q 2024
14 May 24
8-K
Other Events
8 May 24
424B5
Prospectus supplement for primary offering
7 May 24
424B5
Prospectus supplement for primary offering
6 May 24
10-Q
2024 Q1
Quarterly report
6 May 24
8-K
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
6 May 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
PRE 14A
Preliminary proxy
16 Apr 24
8-K
3 Agenda ▪ Business Update ▪ Our Research Strategy ▪ Our Platform ▪ Lead Candidates ▪ Forward Looking ▪ Closing Remarks ▪ Q&A
9 Apr 24
Transcripts
ADCT
Earnings call transcript
2024 Q1
6 May 24
ADCT
Earnings call transcript
2023 Q4
13 Mar 24
ADCT
Earnings call transcript
2023 Q3
7 Nov 23
ADCT
Earnings call transcript
2023 Q2
8 Aug 23
ADCT
Earnings call transcript
2023 Q2
8 Aug 23
ADCT
Earnings call transcript
2023 Q1
9 May 23
ADCT
Earnings call transcript
2022 Q4
28 Feb 23
ADCT
Earnings call transcript
2022 Q3
9 Nov 22
ADCT
Earnings call transcript
2022 Q2
9 Aug 22
ADCT
Earnings call transcript
2022 Q1
9 May 22
Latest ownership filings
4
Jeremy Green
10 May 24
4
AMEET MALLIK
9 May 24
144
Notice of proposed sale of securities
7 May 24
SC 13G
Oaktree Capital Group Holdings GP, LLC
3 May 24
SC 13D/A
AUVEN THERAPEUTICS HOLDINGS LP
25 Apr 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
Prosight Management, LP
13 Feb 24
SC 13G/A
ASTRAZENECA PLC
12 Feb 24
4
Jeremy Green
9 Feb 24
3
Jeremy Green
9 Feb 24
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q4 2023
21.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 0 |
Closed positions | 35 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 691.58 mm |
Total shares | 18.04 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
HPWH TH | 7.45 mm | $275.20 mm |
Auven Therapeutics | 6.33 mm | $12.28 mm |
AZN Astrazeneca | 4.01 mm | $0.00 |
Indie Asset Partners | 92.70 k | $153.88 mm |
Miracle Mile Advisors | 84.50 k | $140.26 mm |
Hennion & Walsh Asset Management | 65.94 k | $109.45 mm |
Focused Wealth Management | 300.00 | $498.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 May 24 | Redmile | Pre-Funded Warrants Common Shares | Buy | Acquire P | Yes | No | 4.812 | 8,163,265 | 39.28 mm | 8,163,265 |
8 May 24 | Redmile | Pre-Funded Warrants Common Shares | Buy | Acquire P | No | No | 4.812 | 6,107,181 | 29.39 mm | 6,107,181 |
7 May 24 | Ameet Mallik | Common Shares | Sell | Dispose S | No | No | 4.48 | 29,731 | 133.19 k | 1,167,348 |
7 Feb 24 | Redmile | Cash-settled Swaps Common Shares | Buy | Acquire P | No | No | 3.9913 | 107,590 | 429.42 k | 107,590 |
2 Feb 24 | Redmile | Cash-settled Swaps Common Shares | Buy | Acquire P | Yes | No | 3.5872 | 11,159 | 40.03 k | 11,159 |
2 Feb 24 | Redmile | Cash-settled Swaps Common Shares | Buy | Acquire P | No | No | 3.5872 | 144,517 | 518.41 k | 144,517 |
1 Feb 24 | Redmile | Cash-settled Swaps Common Shares | Buy | Acquire P | Yes | No | 3.5105 | 15,867 | 55.70 k | 15,867 |
1 Feb 24 | Redmile | Cash-settled Swaps Common Shares | Buy | Acquire P | No | No | 3.5105 | 205,483 | 721.35 k | 205,483 |
1 Feb 24 | Redmile | Cash-settled Swaps Common Shares | Other | Dispose J | Yes | No | 3.3848 | 19,700 | 66.68 k | 1,180,136 |
31 Jan 24 | Redmile | Cash-settled Swaps Common Shares | Buy | Acquire P | No | No | 3.2605 | 150,000 | 489.08 k | 150,000 |
News
HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Lowers Price Target to $8
7 May 24
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session
6 May 24
ADC Therapeutics Q1 2024 Adj EPS $(0.38) Beats $(0.56) Estimate, Sales $18.053M Miss $18.102M Estimate
6 May 24
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA in Patients with Relapsed/Refractory Marginal Zone Lymphoma
6 May 24
Medifast Reports Mixed Results, Joins Coursera, Chegg And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
30 Apr 24
Press releases
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
15 May 24
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
9 May 24
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
6 May 24
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
6 May 24
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
6 May 24